

Prabhakar Rajan



Research Interests

My main research areas are in RNA-binding proteins and alternative pre-mRNA splicing in prostate cancer biology, as well as clinical aspects of treatment for prostate cancer.

My research group focuses on:

- The role and functions of RNA-binding proteins in the metastatic and treatment-resistant prostate cancer phenotypes.
- Identification of mRNA targets for RNA-binding proteins in prostate cancer using high-throughput next generation sequencing-based techniques.
- Transcriptomic analyses of clinical prostate cancer using next generation RNA sequencing (RNA-Seq).
- Clinical and epidemiological aspects of prostate cancer treatments.

Major Funders

- Cancer Research UK
- Royal College of Surgeons of England
- Orchid Charity

Contact Details

Email: p.rajan@qmcr.qmul.ac.uk

Prabhakar Rajan



Recent Publications

- The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P. *Sci Rep.* 2015; 5:13426
- Feasibility study of a randomised controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Rajan P, Frew JA, Wilson JM, Azzabi AST, McMenemin RM, Stockley J, Soomro NA, Durkan G, Pedley ID, Leung HY. *Urol Oncol.* 2015; 33(8):337.e1-6
- Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin RM, Pedley ID, Leung HY. *BMC Cancer.* 2014; 14:977
- The RNA-binding protein hnRNPA2 regulates β -catenin protein expression and is over-expressed in prostate cancer. Stockley J, Villasevil MEM, Nixon C, Ahmad I, Leung HY, Rajan P. *RNA Biol.* 2014; 11(6)
- Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. Rajan P, Sudbery IM, M. Eugenia M. Villasevil MEM, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID, Leung HY. *Eur Urol.* 2014; 66(1):32-9

